• PDF / 169,481 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 76 Downloads / 127 Views

DOWNLOAD

REPORT

---

1 S

Hypoglycaemia: 3 case reports A retrospective cohort study of 273 type 2 diabetes mellitus patients, who failed to respond to metformin monotherapy for at least 3 months, described three patients [ages and sexes not stated], who developed hypoglycaemia during treatment with acarbose, metformin or repaglinide for type 2 diabetes mellitus [routes, durations of treatments to reactions onsets and outcomes not stated; not all dosages stated]. The patients had type 2 diabetes mellitus and had failed to respond to metformin monotherapy for at least 3 months. Therefore, the patients started receiving treatment with acarbose 50mg three times a day plus metformin (2 patients) and repaglinide 1mg three times a day plus metformin (1 patient). The dose of acarbose was force titrated to 100mg three times a day and the dose of repaglinide was force titrated to 2mg three times a day. However, the patients developed treatment-related hypoglycaemia (n=3). Out of the 2 patients, who received acarbose and metformin, one patient developed hypoglycaemic symptoms with fasting blood glucose levels between 2.5 and 3.9 mmol/L and other patient developed hypoglyacemic symptoms with fasting blood glucose levels